Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026)

Altimmune (ALT) posted quarterly Amortization of Deferred Charges of $218000.0 for Q1 2026, up 13.54% quarter-over-quarter from $192000.0 in Q4 2025.

Analysis

Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends

Altimmune (ALT) has reported Amortization of Deferred Charges for 5 consecutive years, with $218000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $218000.0; the TTM figure through Mar 2026 stood at $583587.0 (changed N/A YoY), while the FY2025 annual figure was $363000.0, changed N/A from the prior year.
Amortization of Deferred Charges advanced to $218000.0 in Q1 2026 per ALT's latest filing, from $192000.0 in the prior quarter.
Across five years, Amortization of Deferred Charges topped out at $218000.0 in Q1 2026 and bottomed at $113000.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Altimmune	636.07 Mn	636.07 Mn	-

Historic Data

Download Data